mProX™ Human PLK1 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

PLK1 (Polo-like kinase 1) is a kinase that plays a crucial role in regulating cellular division. It coordinates protein degradation during the G2/M phase of the cell cycle by promoting the binding of substrates to the E3 ubiquitin ligase SCF βTrCP. PLK1 shapes the mitotic proteome by promoting proteolysis through SCF-family E3 ligases. It has been found to regulate the degradation of several proteins, including substrates of the cell cycle E3 SCF Cyclin F. Additionally, PLK1 has been linked to the cell cycle control protein kinase A anchoring protein AKAP2, which is regulated by PLK1/βTrCP-signaling axis. PLK1 has potential implications in malignancies where it is aberrantly regulated. In glioma, the E3 ligase TRIM26 has been identified as an important regulator of GPX4, an enzyme involved in ferroptosis. TRIM26 catalyzes the ubiquitination of GPX4, promoting its stability and suppressing ferroptosis. The interaction between TRIM26 and GPX4 is enhanced by PLK1-mediated phosphorylation of TRIM26. In cutaneous T cell lymphoma, PLK1 has been found to be a target for inducing apoptosis. In vitro evaluation of Neosetophomone B, a potential treatment for cutaneous T cell lymphoma, showed that it downregulated the expression of PLK1 and other proteins involved in cell cycle regulation. Finally, PLK1 inhibitors have been investigated for their effects on Osimertinib-resistant NCI-H1975 cell lines. PLK1 inhibitors showed a stronger anti-tumor effect when combined with Osimertinib, suggesting their potential use for intervention and treatment of Osimertinib resistance in non-small cell lung cancer. Overall, PLK1 has diverse applications in cell cycle control, protein degradation, ferroptosis regulation, apoptosis induction, and overcoming drug resistance in cancer therapy.